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PAlthough the U.S. spends more on medical care than any country in the world, Americans live
shorter lives than the citizens of other high-income countries. Many important opportunities to
improve this record lie outside the health sector and involve improving the conditions in which
Americans live and work: safe design and maintenance of roads, bridges, train tracks, and airports;
control of environmental pollutants; occupational safety; healthy buildings; a safe and healthy food
supply; safe manufacture of consumer products; a healthy social environment; and others. Faced
with the overwhelming array of possibilities, U.S. decision makers need help identifying those that
can contribute the most to health. Cost-effectiveness analysis is designed to serve that purpose, but
has mainly been used to assess interventions within the health sector. This paper brieﬂy reviews the
objective of cost-effectiveness analysis and its methodologic evolution and discusses the issues that
arise when it is used to evaluate interventions that fall outside the health sector under three headings:
structuring the analysis, quantifying/measuring beneﬁts and costs, and valuing beneﬁts and costs.
(Am J Prev Med 2016;50(5S1):S6–S12)& 2016 American Journal of Preventive Medicine. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionAlthough the U.S. spends more on medical carethan any country in the world, Americans liveshorter lives than the citizens of other high-
income countries. U.S. life expectancy has been falling in
the international rankings for decades: As medical
spending rose from 8.9% of national income in 1980 to
17.4% in 2013, life expectancy fell from about average for
high-income countries to nearly the lowest.1,2 What can
be done to reverse this situation?
Public health has come to realize, or, perhaps more
accurately, has returned to the realization,3 that health is not
solely or even primarily a matter of medical care, but of the
total environment in which human beings live and work.
Many opportunities to improve U.S. life expectancy lie
outside the health sector: safe design and maintenance of
roads, bridges, train tracks, and airports; control of environ-
mental pollutants; occupational safety; healthy buildings; a
safe and healthy food supply; safe manufacture of consumer
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open access article under the CC BY-NCdeﬁnes the scope of environmental health as covering “the
natural and built environments at local, national, and global
levels” and has issued reports addressing health topics as
varied as the food supply chain, occupational health, and the
relation between oceans and human health.4
Good health is not just a matter of opportunities for
improving health, but also of making good choices among
those opportunities. Faced with so many possibilities,
Americans and the decision makers who represent them
need help identifying those that contribute the most to
health. Cost-effectiveness analysis (CEA), which has primar-
ily been applied to interventions in the health sector, has
proven a useful guide. The goals of public health and CEA
are one and the same: tomaximize the health of a population.
CEA’s methodology is designed to identify investments that
contribute the most to better health,5,6 and is useful for
investments from prevention to treatment.7–9 Perhaps not
coincidentally, CEA plays a larger part in decision making
about health in many other high-income countries, all of
which have longer life expectancies, than it does in the U.S.6
How can CEA be made more useful to U.S. decision
makers as they consider interventions outside the health
sector? Why does it need to be? This paper explores how
the design of CEA might be modiﬁed to address such
interventions. It begins by providing some brief back-
ground on CEA: its goal and methodologic evolution
over the last several decades and the development of the
concept of the reference case. It then examines the issues
that arise in using CEA to evaluate potential health
investments that fall largely or entirely outside the healthnal of Preventive Medicine  Published by Elsevier Inc. This is an
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the ﬁeld move forward so that CEA can more usefully
contribute to good decisions about public health
investments.
Goal and Evolution of Cost-Effectiveness
Analysis
Both public health and CEA aim to improve the health of
populations. CEA evaluates the costs and health effects of
interventions and summarizes the results in cost-
effectiveness ratios, for example, the cost per year of life
gained. A general measure of health outcome, such as
life-years or quality-adjusted life-years (QALYs), makes
it possible to compare very different health interventions.
The attention to costs has led some to see CEA as a
method of cost control, but two things required for cost
control are missing: CEA does not set budgets or
spending limits; and it does not tell decision makers
what they can or cannot choose, but only suggests
priorities. Budgets or spending limits control spending.
It is easier to see that health is the goal if cost-effectiveness
ratios are used to calculate the number of QALYs that could
be purchased for a given outlay, say $1 million. Smoking-
cessation programs, for example, at $6,200 per QALY gained
(2013 dollars), would yield 161 healthy years for $1
million.6,10 At $36,000 per QALY, mammograms every 2
years to screen for breast cancer in women aged 5079 years
would yield 28 healthy years.6,11 Both are productive invest-
ments in health—they yield better health. If the budget will
cover both, both should be offered. CEA only suggests that, if
the budget will not cover both, and if the goal is the most
health for the population, it is worthwhile to consider
providing smoking cessation rather than breast cancer
screening. CEA suggests priorities for situations in which
not everything can be purchased.
In the course of its development over the last 40 years,
CEA has built on advances in many other ﬁelds. New
developments in simulation modeling, one of CEA’s
basic tools, and standards for simulation models, includ-
ing uncertainty analysis, have been important to improv-
ing the quality of analyses.12,13 The methodologies of
systematic review and meta-analysis have contributed to
better estimates of the parameters needed for CEA
models. Preferred Reporting Items for Systematic
Reviews and Meta-Analyses14 and the Cochrane Com-
munity Reviews15 have been particularly inﬂuential, as
have reports like IOM’s Finding What Works in Health
Care: Standards for Systematic Reviews.16
One of the most important advances in CEA has been the
organizing concept of the reference case. As the example of
smoking cessation andmammograms illustrates, the point of
CEA is to compare alternatives and choose those thatMay 2016contribute most to health. Analyses will necessarily differ
because of the nature of the disease, the outcomes associated
with it, the nature and costs of possible interventions, and the
ways in which the features of the disease and the inter-
ventions vary from one jurisdiction, or one group of patients,
to another. But they should not differ because of methodo-
logic choices that are not necessary to reﬂect those real and
important differences. A consistent and comprehensive set of
standards for CEAs helps decision makers reach the right
decisions.
The reference case concept has been developed to meet
the needs of decision makers around the world. A partial
list of groups that have established reference case stand-
ards for the conduct of CEAs includes: the U.S. Panel on
Cost-Effectiveness in Health and Medicine,5 the United
Kingdom’s National Institute for Health and Clinical
Excellence,17 the Canadian Agency for Drugs and Tech-
nologies in Health,18 the Australian Pharmaceutical
Beneﬁts Advisory Committee,19 WHO,20 and the Bill
and Melinda Gates Foundation.21 No two reference cases
are the same, but they share common elements:1. Reference cases typically focus on the costs of the
formal health sector—sometimes the entire formal
health sector, more often the costs of a particular
payer or payers. Though some recommend including
costs and beneﬁts outside the health sector, they
provide little guidance on how to do so.2. Reference cases typically recommend the use of a
summary measure of health that allows the health
consequences of different diseases and interventions
to be compared. High-income countries use one of
several systems for calculating QALYs gained from an
intervention.5 Low- and middle-income countries
generally use disability-adjusted life-years averted.223. Because modeling is an essential tool in CEAs, reference
cases usually discuss standards for modeling, such as the
range of interventions to be modeled, the time horizon
for the analysis, and methods for exploring uncertainty
in the data used to inform model parameters.4. The groups that have developed reference cases agree
that CEA is one element in decision making. Deci-
sions may involve other factors—ethical issues or
feasibility and logistic factors—that lead to choices
that do not follow the strict ordering of options
presented in a CEA.
Issues Raised by Interventions Outside the
Health Sector
Reference cases, which currently focus on the health
sector, need to be revised to provide guidance when CEA
is used to evaluate broader public health interventions.
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tions is a comprehensive perspective that attempts to
measure all beneﬁts and costs, no matter whether they
occur inside or outside the health sector. Outside the
health sector, this kind of comprehensive analysis has
mainly been conducted using costbeneﬁt analysis
(CBA). CBA differs from CEA only in that it applies a
monetary valuation to all outcomes, not just resources
used; any CEA can be turned into a CBA by multiplying
the health outcomes by a monetary valuation. There is a
large literature on the methods used to derive such
monetary values. The ﬁnal summary of a CBA is net
monetary beneﬁt: the monetary value of all beneﬁts
minus the monetary value of all resources used.23,24
Within the ﬁeld of CEA, however, with its tradition of
focusing on health and the health sector, there is no
general consensus on what this comprehensive perspec-
tive is or how to apply it. The U.S. Panel on Cost-
Effectiveness in Health and Medicine, for example,
recommended that beneﬁts and costs outside the health
sector be included in CEA, but gave little guidance how to
do that. IOM, the Second Panel on Cost-Effectiveness
Analysis in Health and Medicine, and the National
Institute for Health and Clinical Excellence, among
others, have debated more speciﬁc guidance for a
comprehensive perspective.25,26
A comprehensive perspective raises issues at every step
of an analysis: structuring the analysis, measuring costs
and beneﬁts in natural units, and valuing costs and
beneﬁts. Keeping the steps conceptually separate is
important to developing good guidance. Combining
steps can lead to errors, particularly at the later steps,
where measuring and valuing can sometimes be confused
with each other.Structuring the Analysis
Structuring an analysis encompasses tasks familiar to any
CEA analyst, among them specifying the target popula-
tion, the alternatives to be evaluated, the costs and
beneﬁts to measure, and the time horizon over which
to evaluate them.5 Identifying costs and beneﬁts outside
the health sector, unfamiliar territory for CEA analysts,
can be difﬁcult. At the identiﬁcation step, analysts can
use the strategy that has served them well for health
interventions: review the literature and consult a range of
subject experts.
A 2012 IOM report, An Integrated Framework for
Assessing the Value of Community-Based Prevention,25
addresses the issue of identifying all important conse-
quences. It states that: “[t]he valuation of community-
based prevention interventions should be done with a
comprehensive perspective; that is, the measurement ofbeneﬁts, harms, and resources should include impacts on
all members of the community as well as on stakeholders
who may be outside the community.” The ﬁrst recom-
mendation identiﬁes three broad and mutually exclusive
categories of beneﬁts and costs: “The committee recom-
mends that those seeking to assign value to community-
based prevention interventions take a comprehensive
view that includes the beneﬁts and harms in the three
major domains of health, community well-being, and
community process as well as the resource use associated
with such interventions.” The IOM report explains:
Community-based prevention can create value not
only through improvements in the health of individ-
uals but also by increasing the investment that
individuals are willing and able to make in themselves,
in their family and neighbors, and in their environ-
ment. Furthermore, community-based prevention
involves decisions among groups of people about
how to live in society, how the physical environment
is built, what food is served in schools, and so on.
Thus, the process by which interventions are decided
upon and undertaken needs to be treated as a valued
outcome. If a community decides to tell people what
they can or cannot do, or what they should or should
not do, the decisions need to have the legitimacy—the
added value—that comes from an open and inclusive
group decision-making process.
No accepted measures exist for the second two
classes of beneﬁt. The committee recommended that
the Centers for Disease Control and Prevention (CDC)
develop some.
A simple example can illustrate the three domains
identiﬁed by the IOM report.25 Suppose a community
invests in a park with trails and night-time lighting to
encourage people to walk and engage in other physical
activity for their health. The list of possible beneﬁts
certainly includes health, which the IOM report recom-
mended be measured in QALYs, but the park can also
bring aesthetic beneﬁts (people can enjoy the park’s
beauty whether they walk or not) and safety beneﬁts (if
the lighting reduces crime in the area). If decisions about
the park are made with community involvement, to
ensure that the community contributes to the plans, the
beneﬁts can include a greater sense of cohesion and pride
on the part of community members.
Costbeneﬁt analysts routinely face the same issue. As
noted, the perspective usually taken in a CBA is
comprehensive—the societal perspective—and encom-
passes all signiﬁcant beneﬁts or costs that occur in the
jurisdiction of the decision maker. For example, in its
2011 evaluation of the Clean Air Act Amendments of
1990, which estimated costs and beneﬁts over thewww.ajpmonline.org
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Agency valued reductions in mortality and illness;
improvements in visibility at recreational sites and in
residential areas; beneﬁts to commercial timber, agricul-
tural crops, and recreational ﬁshing; and reduced materi-
als damage.27Measuring Beneﬁts and Costs
One of CEA’s major contributions to decision making is
that it not only lists the beneﬁts and costs of an
intervention, but also measures their magnitude. Quan-
tifying them gives a clearer idea of their size and
importance. The measurement process uses “natural
units,” such as familiar health metrics—cases of disease,
deaths prevented, and life-years and QALYs gained by an
intervention. Thus, the next step is to select metrics that
allow each cost or beneﬁt to be measured.
Interventions that take place largely or entirely outside
the health sector can involve metrics new to CEA analysts
as they seek to quantify the intervention’s effects on the
aesthetic environment, crime and safety, and others. At
this stage, costs (resources used by the intervention) are
also best measured in physical units if data are available.
As noted, existing measures for many beneﬁts and costs,
such as levels of smog and air pollution, rates of property
and violent crime, test scores and years of schooling,
housing quality, and trafﬁc safety, can be identiﬁed by
experts in each subject area.
Analysts also need to measure all the resources used by
an intervention. Perhaps even more than interventions
that take place in the health sector, those that take place
largely or entirely outside it can involve substantial
amounts of donated resources. The temptation is to
consider these resources as costing nothing—as free—
because no check changes hands for them. Donated time,
goods, and services are not free unless they would have
gone completely unused had this project not come along.
The Community Preventive Services Task Force makes
this point, correctly noting that all resources, whether
purchased or donated, should be included in costs.28
Consider the park example again. People may donate
trees and plants for the landscaping. They may volunteer
their time for planning, carrying out the plans, and
maintaining the park once it has been created. Some
businesses encourage employees to spend paid work time
on community activities. Donated time and goods and
services are as much resource costs of the project as are
purchased labor and materials.Valuing and Summarizing
Once beneﬁts and costs are measured in natural units,
how should they be valued? Why should they be valued?May 2016Or is a detailed table listing beneﬁts and costs in natural
units enough?
Valuation involves weighting beneﬁts and resources
after they have been measured in natural units so that
they can be combined and summarized. To make
summarization possible, it attaches a second number to
each that reﬂects people’s preferences: A higher number
indicates a higher value. Using a consistent principle for
valuation, and a common unit of measure for the values,
as CBA does when it uses the principle of willingness to
pay (WTP) to translate beneﬁts and costs into dollars,
allows beneﬁts and costs to be combined in an overall
summary. For a given decision, the detailed table of costs
and beneﬁts in natural units can and should be presented
to decision makers, but they may also ﬁnd summary
measures helpful for comparing choices. In CEA, there
are two summary measures, one for health and one for
resources used. In CBA, a single summary measure, net
beneﬁt, is possible because both beneﬁts and resources
are valued in monetary terms.
Valuing beneﬁts and costs in order to summarize them
can be the most difﬁcult part of an analysis. It can be easy
to value some beneﬁts twice, such as the portion of health
used for paid work, which then biases the summary in
favor of interventions that produce particular kinds of
health or health for particular kinds of people. The
tendency to count donations as costing nothing biases
the summary in another way, toward interventions that
involve donated time, goods, and services.
Finding or developing appropriate measures of value,
measures that reﬂect how the community values beneﬁts
and costs, can also be difﬁcult. In thinking about how to
value beneﬁts and costs, CEA can learn from the
experience of CBA. For example, CBA used to value
health as the additional earnings healthier people could
make.29 That tradition is still widely inﬂuential outside of
economics, but economists began to realize in the 1960s
and 1970s that labor market earnings were the wrong
way to value health because that is not how people
themselves value it. For example, earnings assign no
value to other activities made possible by better health—
taking care of children or the elderly, maintaining the
house, socializing, sleeping—although people clearly do
value these activities. By the 1980s, economists agreed
that the basic economic principle of WTP was the right
way to approach valuing life and health and the concept
“that social decisions should, so far as possible, reﬂect the
interests, preferences and attitudes to risk of those who
are likely to be affected by the decisions”—had been
“extensively developed in the literature.”30 The Environ-
mental Protection Agency was already applying the
principle in the mid-1980s.31 In its CBA standards, the
U.S. Ofﬁce of Management and Budget states: “In
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conceptually appropriate measure as compared to other
alternatives (e.g., cost of illness or lifetime earnings), in
part because it attempts to capture pain and suffering and
other quality-of-life effects.”32
How can WTP be used to value life and health? The
answer begins with the recognition that people act on
their values all the time, revealing them through the
choices they make. Some of those choices occur in
markets, where people reveal how much they value a
good or service through the amount they are willing to
spend for it. Life and health are not sold in markets, but
economists realized that goods and services sold in
markets often reﬂect people’s valuation of non-market
goods. Purchases of safety equipment to prevent acci-
dents, for example, reveal a WTP for better health and
longer life. Similarly, higher pay is required for dangerous
jobs because workers value life and health.33 Economists
have used this “risk premium,” the extra money per hour
of work, to calculate the “value of a statistical life” (VSL;
the value of a statistical life-year, VSLY, can be derived
from VSL32) and have found that it implies a high
valuation on life and health. Based on wage-risk studies,
the Environmental Protection Agency currently uses a
VSL of $7.4 million (2006 dollars) to value reductions in
mortality due to less pollution.
The WTP principle explains an apparent paradox ﬁrst
noted when labor market earnings were still used to value
health: People were often willing to contribute large sums
to rescue others in distress, sums much larger than the
earnings used to value life saving in CBA. The explan-
ation proposed at the time was that people valued
“identiﬁed” lives—real people in real crises—more highly
than they valued “statistical” lives, the future and
unidentiﬁed lives that would be saved by, say, introduc-
ing safety gear on the job or repairing bridges. Once,
however, economists began to estimate what people were
willing to pay for life saving, VSL turned out to be much
higher than lost earnings and in line with the amounts
they contribute to save identiﬁed lives.34
Another principle borrowed from CBA is that the
resources used by an intervention should be valued at
their opportunity cost, which reﬂects the value of the
goods and services that would be produced if the
resources were put to their next-best use. In effect,
valuation of resources is also based on the principle of
WTP. In perfectly functioning markets—many buyers
and sellers, each fully informed about the product, where
beneﬁts accrue only to buyers, costs only to sellers—
prices would reﬂect this opportunity cost. Even imperfect
market prices are often good proxies for opportunity
costs. When prices are not available, as for resources that
are not sold in markets, market prices for other goodscan, again, often offer evidence about the value people
place on those resources. This explains economists’
practice of valuing time spent in activities other than
paid employment at the wage for paid work: By choosing
unpaid activities, people indicate that they value time
spent on those activities at least as highly as the wage they
could earn with that time.35 A distinction is sometimes
drawn between the valuation of things sold in markets
and those not sold in markets,28 but the economic
principle does not make such a distinction. Both kinds
of resources are valued at their opportunity costs and
have thus been translated into comparable terms using a
consistent principle.
Conclusions
Where does this point us? Just as CEA has adopted
helpful CBA practices in the past, it can beneﬁt from
considering the way CBA handles the valuation of
beneﬁts and costs that fall outside the health sector as
it begins to develop standards for this kind of application.
There is no ready-made solution available and, in any
event, the solution must be developed out of a consensus
among analysts and decision makers. The following
principles, however, may help lead to a good solution:1. In democratic societies, outcomes should be valued
as the affected people value them. CEA, which
derives QALY weights from surveys, and CBA,
which derives monetary values from market choices
(and, when those are lacking, surveys), agree on this
principle.2. As it has in the past, the experience of CBA can help
CEA analysts develop ways to value more outcomes
in monetary terms and do so in a consistent way.
But, it is important that CEA analysts inform
themselves of current thinking in CBA and consider
its implications before developing general
recommendations.3. CBA has the strength that everything can be
monetized, so that the sum of costs can be deducted
from the sum of beneﬁts to show whether an
intervention is beneﬁcial when the potentially wide
array of beneﬁts and costs involved in nonhealth
sector interventions is considered. CEA has the
strength that it focuses directly on health, the out-
come of primary interest, using a measure of health.
For now, it seems best to follow the advice of the U.S.
Ofﬁce of Management and Budget and do both, in
order to give decision makers a full pictures of the
consequences of an intervention.32,364. In either form of analysis, beneﬁts and costs
should always be presented in a disaggregatedwww.ajpmonline.org
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Mayway, so that decision makers can clearly see the
components.5. CEA summarizes results with cost-effectiveness
ratios, CBA with net monetary beneﬁt. Both can
calculate those summaries in a variety of ways
when there are many beneﬁts and costs involved.
For example, CEA can calculate the health sector
cost per QALY, the total cost per QALY, and the net
cost (costs less monetized non-health beneﬁts) per
QALY. CBA can calculate net beneﬁts for health
effects and health sector costs or for wider sets of
beneﬁts and costs; for example, in the case of the
park, including only aesthetic beneﬁts in one sum-
mary and both crime reduction and aesthetic bene-
ﬁts in another. CEA analysts and decision makers
need to explore the range of possible summary
measures before arriving at a consensus, if one is
possible, about those that are conceptually consistent
and best serve the needs of public health decision
makers.Publication of this article was supported by the Centers for
Disease Control and Prevention.
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